<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39417044</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2732-494X</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>1</Issue><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Antimicrobial stewardship &amp; healthcare epidemiology : ASHE</Title><ISOAbbreviation>Antimicrob Steward Healthc Epidemiol</ISOAbbreviation></Journal><ArticleTitle>Impact of a remdesivir formulary restriction by antimicrobial stewardship on drug utilization and cost at a safety-net community hospital during the COVID-19 pandemic.</ArticleTitle><Pagination><StartPage>e164</StartPage><MedlinePgn>e164</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e164</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1017/ash.2024.438</ELocationID><Abstract><AbstractText>Deploying novel COVID-19 therapies proved challenging amid rapidly evolving data, drug shortages, and conflicting guidelines. We established a remdesivir formulary restriction remdesivir to promote its evidence-based use. This intervention led to changes in remdesivir utilization patterns and cost savings. Formulary restrictions can play an important role in pandemic preparedness and response.</AbstractText><CopyrightInformation>© The Author(s) 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mena Lora</LastName><ForeName>Alfredo Jose</ForeName><Initials>AJ</Initials><Identifier Source="ORCID">0000-0002-8337-757X</Identifier><AffiliationInfo><Affiliation>University of Illinois at Chicago, Chicago, IL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Saint Anthony Hospital, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huber</LastName><ForeName>Dylan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Saint Anthony Hospital, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ella</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Saint Anthony Hospital, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lavani</LastName><ForeName>Romeen</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Saint Anthony Hospital, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ali</LastName><ForeName>Mirza</ForeName><Initials>M</Initials><Identifier Source="ORCID">0009-0001-4598-7123</Identifier><AffiliationInfo><Affiliation>Saint Anthony Hospital, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takhsh</LastName><ForeName>Eden</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Saint Anthony Hospital, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burgos</LastName><ForeName>Rodrigo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>University of Illinois at Chicago, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Antimicrob Steward Healthc Epidemiol</MedlineTA><NlmUniqueID>9918266096106676</NlmUniqueID><ISSNLinking>2732-494X</ISSNLinking></MedlineJournalInfo><CoiStatement>All authors report no conflicts of interest relevant to this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>10</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>10</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>5</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39417044</ArticleId><ArticleId IdType="pmc">PMC11474786</ArticleId><ArticleId IdType="doi">10.1017/ash.2024.438</ArticleId><ArticleId IdType="pii">S2732494X24004388</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 — final report. New Engl J Med 2020;383(19):1813–1826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7262788</ArticleId><ArticleId IdType="pubmed">32445440</ArticleId></ArticleIdList></Reference><Reference><Citation>
National Institutes of Health. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Accessed January 20, 2023. https://covid19treatmentguidelines.nih.gov/
</Citation><ArticleIdList><ArticleId IdType="pubmed">34003615</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious diseases society of america guidelines on the treatment and management of patients with COVID-19. Clin Infect Dis Published online September 5, 2022. doi: 10.1093/cid/ciac724</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac724</ArticleId><ArticleId IdType="pmc">PMC9494372</ArticleId><ArticleId IdType="pubmed">36063397</ArticleId></ArticleIdList></Reference><Reference><Citation>
World Health Organization. Guideline Therapeutics and COVID-19: Living Guideline. 2023. http://apps.who.int/bookorders.</Citation><ArticleIdList><ArticleId IdType="pubmed">35917393</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Solidarity Trial Consortium. Repurposed antiviral drugs for Covid-19 — interim WHO solidarity trial results. New Engl J Med 2021;384(6):497–511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7727327</ArticleId><ArticleId IdType="pubmed">33264556</ArticleId></ArticleIdList></Reference><Reference><Citation>Stenehjem E, Hyun DY, Septimus E, et al. Antibiotic stewardship in small hospitals: barriers and potential solutions. Clinl Infect Dis 2017;65(4):691–696.</Citation><ArticleIdList><ArticleId IdType="pubmed">28472291</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu A. Gilead’s long-awaited remdesivir price is $3,120, in line with watchdog estimates. Fierce Pharma.</Citation></Reference><Reference><Citation>Zeitler KE, Piccicacco N, Jariwala R, Montero J, Kim K. The impact of an antimicrobial stewardship program restriction on remdesivir prescribing. Antimicrob Steward Healthc Epidemiol 2022;2(1):e149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9726504</ArticleId><ArticleId IdType="pubmed">36483438</ArticleId></ArticleIdList></Reference><Reference><Citation>Mena Lora AJ, Burgos R, Borgetti S, Chaisson LH, Bleasdale SC. Remdesivir use and antimicrobial stewardship restrictions during the coronavirus disease 2019 (COVID-19) pandemic in the United States: a cross-sectional survey. Antimicrob Steward Healthc Epidemiol 2023;3(1):e63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10127235</ArticleId><ArticleId IdType="pubmed">37113205</ArticleId></ArticleIdList></Reference><Reference><Citation>Mena Lora AJ, Burgos R, Borgetti S, Chaisson LH, Bleasdale SC. Antimicrobial stewardship and drug formulary restrictions during COVID-19: what is restricted and who decides? Antimicrob Steward Healthc Epidemiol 2023;3(1):e116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10369429</ArticleId><ArticleId IdType="pubmed">37502239</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>